Elotuzumab second line or third line regimen following a Proteasome-IMiD based combination

Morie A. Gertz, MD of Mayo Clinic discusses elotuzumab second line or third line regimen following a Proteasome-IMiD based combination Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.